High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG

Kaori Miyazaki-Komine, Yoshiki Takai, Ping Huang, Osamu Kusano-Arai, Hiroko Iwanari, Tatsuro Misu, Katsushi Koda, Katsuyuki Mitomo, Toshiko Sakihama, Yoshiaki Toyama, Kazuo Fujihara, Takao Hamakubo, Masato Yasui, Yoichiro Abe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Purpose Most of the cases of neuromyelitis optica (NMO) are characterized by the presence of an autoantibody, NMO-IgG, which recognizes the extracellular domains of the water channel, aquaporin-4. Binding of NMO-IgG to aquaporin-4 expressed in end-feet of astrocytes leads to complement-dependent disruption of astrocytes followed by demyelination. One therapeutic option for NMO is to prevent the binding of NMO-IgG to aquaporin-4, using high-avidity, non-pathogenic-chimeric, monoclonal antibodies to this water channel. We describe here the development of such antibodies. Experimental Approach cDNAs encoding variable regions of heavy and light chains of monoclonal antibodies against the extracellular domains of human aquaporin-4 were cloned from hybridoma total RNA and fused to those encoding constant regions of human IgG1 and Igκ respectively. Then mammalian expression vectors were constructed to establish stable cell lines secreting mature chimeric antibodies. Key Results Original monoclonal antibodies showed high avidity binding to human aquaporin-4, as determined by ELISA. Live imaging using Alexa-Fluor-555-labelled antibodies revealed that the antibody D15107 more rapidly bound to cells expressing human aquaporin-4 than others and strongly enhanced endocytosis of this water channel, while D12092 also bound rapidly to human aquaporin-4 but enhanced endocytosis to a lesser degree. Chimeric D15107 prevented complement-dependent cytotoxicity induced by NMO-IgG from patient sera in vitro. Conclusions and Implications We have established non-pathogenic, high-avidity, chimeric antibodies against the extracellular domains of human aquaporin-4, which provide a novel therapeutic option for preventing the progress and recurrence of NMO/NMO spectrum disorders.

Original languageEnglish
Pages (from-to)103-114
Number of pages12
JournalBritish Journal of Pharmacology
Volume173
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Aquaporin 4
Neuromyelitis Optica
Autoantibodies
Immunoglobulin G
Monoclonal Antibodies
Aquaporins
Antibodies
Endocytosis
Astrocytes
Antibody Affinity
Hybridomas
Demyelinating Diseases
Complementary DNA
Enzyme-Linked Immunosorbent Assay
RNA
Light
Recurrence
Cell Line

ASJC Scopus subject areas

  • Pharmacology

Cite this

High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG. / Miyazaki-Komine, Kaori; Takai, Yoshiki; Huang, Ping; Kusano-Arai, Osamu; Iwanari, Hiroko; Misu, Tatsuro; Koda, Katsushi; Mitomo, Katsuyuki; Sakihama, Toshiko; Toyama, Yoshiaki; Fujihara, Kazuo; Hamakubo, Takao; Yasui, Masato; Abe, Yoichiro.

In: British Journal of Pharmacology, Vol. 173, No. 1, 01.01.2016, p. 103-114.

Research output: Contribution to journalArticle

Miyazaki-Komine, K, Takai, Y, Huang, P, Kusano-Arai, O, Iwanari, H, Misu, T, Koda, K, Mitomo, K, Sakihama, T, Toyama, Y, Fujihara, K, Hamakubo, T, Yasui, M & Abe, Y 2016, 'High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG', British Journal of Pharmacology, vol. 173, no. 1, pp. 103-114. https://doi.org/10.1111/bph.13340
Miyazaki-Komine, Kaori ; Takai, Yoshiki ; Huang, Ping ; Kusano-Arai, Osamu ; Iwanari, Hiroko ; Misu, Tatsuro ; Koda, Katsushi ; Mitomo, Katsuyuki ; Sakihama, Toshiko ; Toyama, Yoshiaki ; Fujihara, Kazuo ; Hamakubo, Takao ; Yasui, Masato ; Abe, Yoichiro. / High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG. In: British Journal of Pharmacology. 2016 ; Vol. 173, No. 1. pp. 103-114.
@article{47611859653144859b63b08cbf1d7392,
title = "High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG",
abstract = "Background and Purpose Most of the cases of neuromyelitis optica (NMO) are characterized by the presence of an autoantibody, NMO-IgG, which recognizes the extracellular domains of the water channel, aquaporin-4. Binding of NMO-IgG to aquaporin-4 expressed in end-feet of astrocytes leads to complement-dependent disruption of astrocytes followed by demyelination. One therapeutic option for NMO is to prevent the binding of NMO-IgG to aquaporin-4, using high-avidity, non-pathogenic-chimeric, monoclonal antibodies to this water channel. We describe here the development of such antibodies. Experimental Approach cDNAs encoding variable regions of heavy and light chains of monoclonal antibodies against the extracellular domains of human aquaporin-4 were cloned from hybridoma total RNA and fused to those encoding constant regions of human IgG1 and Igκ respectively. Then mammalian expression vectors were constructed to establish stable cell lines secreting mature chimeric antibodies. Key Results Original monoclonal antibodies showed high avidity binding to human aquaporin-4, as determined by ELISA. Live imaging using Alexa-Fluor-555-labelled antibodies revealed that the antibody D15107 more rapidly bound to cells expressing human aquaporin-4 than others and strongly enhanced endocytosis of this water channel, while D12092 also bound rapidly to human aquaporin-4 but enhanced endocytosis to a lesser degree. Chimeric D15107 prevented complement-dependent cytotoxicity induced by NMO-IgG from patient sera in vitro. Conclusions and Implications We have established non-pathogenic, high-avidity, chimeric antibodies against the extracellular domains of human aquaporin-4, which provide a novel therapeutic option for preventing the progress and recurrence of NMO/NMO spectrum disorders.",
author = "Kaori Miyazaki-Komine and Yoshiki Takai and Ping Huang and Osamu Kusano-Arai and Hiroko Iwanari and Tatsuro Misu and Katsushi Koda and Katsuyuki Mitomo and Toshiko Sakihama and Yoshiaki Toyama and Kazuo Fujihara and Takao Hamakubo and Masato Yasui and Yoichiro Abe",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bph.13340",
language = "English",
volume = "173",
pages = "103--114",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG

AU - Miyazaki-Komine, Kaori

AU - Takai, Yoshiki

AU - Huang, Ping

AU - Kusano-Arai, Osamu

AU - Iwanari, Hiroko

AU - Misu, Tatsuro

AU - Koda, Katsushi

AU - Mitomo, Katsuyuki

AU - Sakihama, Toshiko

AU - Toyama, Yoshiaki

AU - Fujihara, Kazuo

AU - Hamakubo, Takao

AU - Yasui, Masato

AU - Abe, Yoichiro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background and Purpose Most of the cases of neuromyelitis optica (NMO) are characterized by the presence of an autoantibody, NMO-IgG, which recognizes the extracellular domains of the water channel, aquaporin-4. Binding of NMO-IgG to aquaporin-4 expressed in end-feet of astrocytes leads to complement-dependent disruption of astrocytes followed by demyelination. One therapeutic option for NMO is to prevent the binding of NMO-IgG to aquaporin-4, using high-avidity, non-pathogenic-chimeric, monoclonal antibodies to this water channel. We describe here the development of such antibodies. Experimental Approach cDNAs encoding variable regions of heavy and light chains of monoclonal antibodies against the extracellular domains of human aquaporin-4 were cloned from hybridoma total RNA and fused to those encoding constant regions of human IgG1 and Igκ respectively. Then mammalian expression vectors were constructed to establish stable cell lines secreting mature chimeric antibodies. Key Results Original monoclonal antibodies showed high avidity binding to human aquaporin-4, as determined by ELISA. Live imaging using Alexa-Fluor-555-labelled antibodies revealed that the antibody D15107 more rapidly bound to cells expressing human aquaporin-4 than others and strongly enhanced endocytosis of this water channel, while D12092 also bound rapidly to human aquaporin-4 but enhanced endocytosis to a lesser degree. Chimeric D15107 prevented complement-dependent cytotoxicity induced by NMO-IgG from patient sera in vitro. Conclusions and Implications We have established non-pathogenic, high-avidity, chimeric antibodies against the extracellular domains of human aquaporin-4, which provide a novel therapeutic option for preventing the progress and recurrence of NMO/NMO spectrum disorders.

AB - Background and Purpose Most of the cases of neuromyelitis optica (NMO) are characterized by the presence of an autoantibody, NMO-IgG, which recognizes the extracellular domains of the water channel, aquaporin-4. Binding of NMO-IgG to aquaporin-4 expressed in end-feet of astrocytes leads to complement-dependent disruption of astrocytes followed by demyelination. One therapeutic option for NMO is to prevent the binding of NMO-IgG to aquaporin-4, using high-avidity, non-pathogenic-chimeric, monoclonal antibodies to this water channel. We describe here the development of such antibodies. Experimental Approach cDNAs encoding variable regions of heavy and light chains of monoclonal antibodies against the extracellular domains of human aquaporin-4 were cloned from hybridoma total RNA and fused to those encoding constant regions of human IgG1 and Igκ respectively. Then mammalian expression vectors were constructed to establish stable cell lines secreting mature chimeric antibodies. Key Results Original monoclonal antibodies showed high avidity binding to human aquaporin-4, as determined by ELISA. Live imaging using Alexa-Fluor-555-labelled antibodies revealed that the antibody D15107 more rapidly bound to cells expressing human aquaporin-4 than others and strongly enhanced endocytosis of this water channel, while D12092 also bound rapidly to human aquaporin-4 but enhanced endocytosis to a lesser degree. Chimeric D15107 prevented complement-dependent cytotoxicity induced by NMO-IgG from patient sera in vitro. Conclusions and Implications We have established non-pathogenic, high-avidity, chimeric antibodies against the extracellular domains of human aquaporin-4, which provide a novel therapeutic option for preventing the progress and recurrence of NMO/NMO spectrum disorders.

UR - http://www.scopus.com/inward/record.url?scp=84952637578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952637578&partnerID=8YFLogxK

U2 - 10.1111/bph.13340

DO - 10.1111/bph.13340

M3 - Article

C2 - 26398585

AN - SCOPUS:84952637578

VL - 173

SP - 103

EP - 114

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -